                         SEQUENCE LISTING

<110>  Recopharma AB
 
<120>  Compositions and Methods for Inhibiting Shiga Toxin and 
       Shiga-Like Toxin

<130>  28457-508001WO

<150>  61/051874
<151>  2008-05-09

<160>  2     

<170>  PatentIn version 3.5

<210>  1
<211>  10
<212>  PRT
<213>  Artificial sequence

<220>
<223>  PSGL-1 consensus sequence


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  X at position 1 is alanine (A) or isoleucine (I)

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  X at position 5 is glutamine (Q), proline (P), alanine (A) or 
       arginine (R)

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  X at position 6 is proline (P), leucine (L) or threonine (T)

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X at position 7 is alanine (A), threonine (T), glutamic acid (E) 
       or valine (V)

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  X at position 8 is alanine (A), proline (P) or glycine (G)

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  X at position 9 is threonine (T), methionine (M) or leucine (L)

<400>  1

Xaa Gln Thr Thr Xaa Xaa Xaa Xaa Xaa Glu 
1               5                   10  


<210>  2
<211>  10
<212>  PRT
<213>  Artificial sequence

<220>
<223>  PSGL-1 consensus sequence


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  X at position 2 is glutamine (Q) or methionine (M)

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  X at position 5 is proline (P) or glutamine (Q)

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  X at position 6 is proline (P), leucine (L) or threonine (T)

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  X at position 8 is alanine (A), proline (P) or glycine (G)

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  X at position 9 is threonine (T) or methionine (M)

<400>  2

Ala Xaa Thr Thr Xaa Xaa Ala Xaa Xaa Glu 
1               5                   10  


